GPCR net incomeQ3 2026-$144.76M
GPCR net income was -$144.76M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$65.71M a year earlier. For the full fiscal 2025 it was -$141.20M, compared with -$122.53M in fiscal 2024.
Structure Therapeutics Inc. (GPCR) financials
For the twelve months ended Sep 30, 2026, Structure Therapeutics Inc. reported -$293.88M of net income.
- Net income, TTM
- -$293.88M
- Free cash flow, TTM
- -$277.36M
- EPS, diluted, TTM
- -$1.30
- Cash
- $222.03M
- Market cap
- $1.43B
FY2022FY2025
FY2022FY2025
GPCR revenue and earnings growth
GPCR EPSQ3 2026-$0.66
GPCR diluted EPS was -$0.66 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.37 a year earlier. For the full fiscal 2025 it was -$0.80, compared with -$0.78 in fiscal 2024.
GPCR free cash flowQ3 2026-$105.34M
GPCR free cash flow was -$105.34M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$52.57M a year earlier. For the full fiscal 2025 it was -$225.81M, compared with -$117.93M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Research and development | $225.25M | $108.81M | $70.10M | $36.19M |
| Selling, general and admin | $61.55M | $49.41M | $32.67M | $16.37M |
| Operating income | -$176.56M | -$158.23M | -$102.78M | -$52.56M |
| Pre-tax income | -$140.69M | -$122.22M | -$89.38M | -$51.30M |
| Income tax | $515.0K | $310.0K | $236.0K | $17.0K |
| Net income | -$141.20M | -$122.53M | -$89.62M | -$51.32M |
| EPS, basic | -$0.80 | -$0.78 | -$0.81 | -$5.51 |
| EPS, diluted | -$0.80 | -$0.78 | -$0.81 | -$5.51 |
| Diluted shares | 177.6M | 157.9M | 110.2M | 9.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $799.62M | $169.51M | $129.79M | $26.09M |
| Short-term investments | $646.57M | $714.01M | $337.53M | $64.75M |
| Current assets | $1.57B | $891.21M | $473.61M | $93.09M |
| Total assets | $1.58B | $903.33M | $482.02M | $97.84M |
| Current liabilities | $63.28M | $36.02M | $24.74M | $13.01M |
| Total liabilities | $67.54M | $38.49M | $29.05M | $13.01M |
| Shareholders' equity | $1.52B | $864.84M | $452.97M | -$115.14M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$222.20M | -$116.64M | -$79.49M | -$46.12M |
| Capital expenditures | $3.61M | $1.29M | $2.17M | $155.0K |
| Free cash flow | -$225.81M | -$117.93M | -$81.66M | -$46.27M |
| Investing cash flow | $89.80M | -$358.91M | -$268.34M | -$62.11M |
| Financing cash flow | $762.52M | $515.26M | $451.53M | $29.01M |
| Stock-based compensation | $28.99M | $18.79M | $8.19M | $2.51M |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $134.55M | $100.06M | $66.51M | $68.69M | $58.99M | $54.71M | $42.87M | $33.49M | $32.60M | $22.05M | $20.68M | $20.04M |
| Selling, general and admin | $21.78M | $18.57M | $22.87M | $17.57M | $14.80M | $15.74M | $13.44M | $13.57M | $13.24M | $11.27M | $11.34M | $10.95M |
| Operating income | -$156.33M | -$118.63M | -$89.38M | $23.99M | -$73.79M | -$70.45M | -$56.31M | -$47.06M | -$45.84M | -$33.32M | -$32.02M | -$30.99M |
| Pre-tax income | -$144.59M | -$105.92M | -$75.78M | $33.17M | -$65.60M | -$61.52M | -$46.73M | -$36.34M | -$33.88M | -$25.98M | -$26.01M | -$24.82M |
| Income tax | $171.0K | $234.0K | $190.0K | $170.0K | $108.0K | $139.0K | $98.0K | $136.0K | $92.0K | $53.0K | $29.0K | -$312.0K |
| Net income | -$144.76M | -$106.16M | -$75.97M | $33.00M | -$65.71M | -$61.66M | -$46.83M | -$36.48M | -$33.98M | -$26.03M | -$26.04M | -$24.50M |
| EPS, basic | -$0.66 | -$0.49 | -$0.35 | $0.20 | -$0.37 | -$0.36 | -$0.27 | -$0.21 | -$0.20 | -$0.18 | -$0.19 | - |
| EPS, diluted | -$0.66 | -$0.49 | -$0.35 | $0.20 | -$0.37 | -$0.36 | -$0.27 | -$0.21 | -$0.20 | -$0.18 | -$0.19 | - |
| Diluted shares | 218.6M | 218.0M | 217.3M | - | 175.5M | 172.6M | 172.1M | - | 171.6M | 148.2M | 139.7M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $222.03M | $272.64M | $316.17M | $799.62M | $102.91M | $147.02M | $152.12M | $169.51M | $172.13M | $381.63M | $97.83M | $129.79M |
| Short-term investments | $1.02B | $1.07B | $1.14B | $646.57M | $696.13M | $639.47M | $684.76M | $714.01M | $743.16M | $545.49M | $338.62M | $337.53M |
| Current assets | $1.28B | $1.37B | $1.49B | $1.57B | $814.02M | $799.30M | $849.62M | $891.21M | $923.65M | $937.62M | $449.36M | $473.61M |
| Total assets | $1.33B | $1.43B | $1.51B | $1.58B | $832.16M | $816.44M | $866.55M | $903.33M | $933.22M | $947.03M | $457.23M | $482.02M |
| Current liabilities | $107.10M | $66.11M | $56.98M | $63.28M | $57.53M | $39.03M | $36.49M | $36.02M | $33.43M | $22.66M | $23.59M | $24.74M |
| Total liabilities | $112.55M | $71.01M | $61.03M | $67.54M | $62.14M | $44.36M | $41.91M | $38.49M | $36.42M | $26.00M | $27.41M | $29.05M |
| Shareholders' equity | $1.22B | $1.35B | $1.45B | $1.52B | $770.02M | $772.08M | $824.64M | $864.84M | $896.80M | $921.03M | $429.82M | $452.97M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$101.70M | -$120.11M | $15.23M | -$64.42M | -$51.00M | -$54.56M | -$52.23M | -$36.47M | -$19.70M | -$26.39M | -$34.08M | -$21.73M |
| Capital expenditures | $3.65M | -$42.0K | $1.18M | $1.50M | $1.57M | $232.0K | $314.0K | $16.0K | $685.0K | $427.0K | $162.0K | $1.16M |
| Free cash flow | -$105.34M | -$120.16M | $14.05M | -$65.91M | -$52.57M | -$54.79M | -$52.54M | -$36.48M | -$20.38M | -$26.82M | -$34.24M | -$22.89M |
| Investing cash flow | $50.36M | $74.50M | -$496.95M | $56.14M | -$49.32M | $48.94M | $34.03M | $33.23M | -$189.04M | -$204.51M | $1.42M | -$180.74M |
| Financing cash flow | $734.0K | $2.08M | -$1.74M | $704.99M | $56.20M | $517.0K | $809.0K | $615.0K | -$757.0K | $514.70M | $702.0K | $281.63M |
| Stock-based compensation | $12.73M | $12.63M | $11.64M | $8.07M | $7.50M | $7.51M | $5.92M | $5.83M | $6.02M | $4.20M | $2.74M | $2.10M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 11.91 | 20.75 | 26.16 | 24.81 | 14.15 | 20.48 | 23.29 | 24.74 | 27.63 | 41.38 | 19.05 | 19.14 |
Source: XBRL data Structure Therapeutics Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
GPCR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GPCR | - | - | -$293.88M | - | $1.43B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.36T |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $184.33B |
| VKTX | $0 | - | -$627.20M | - | $3.73B |
| ALT | $41.0K | +105.0% | -$88.09M | -214861.0% | $321.1M |
| PFE | $63.63B | +1.3% | $4.03B | 6.3% | $164.67B |
GPCR FAQ
6 questionsIs GPCR profitable?
No. Structure Therapeutics Inc. reported a net loss of $293.88M for the twelve months ended Sep 30, 2026.How much cash and debt does GPCR have?
Structure Therapeutics Inc. reported $222.03M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is GPCR free cash flow?
Structure Therapeutics Inc. generated -$277.36M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$271.00M less capital expenditures.What is GPCR earnings per share?
Diluted earnings per share were -$1.30 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did GPCR last report financial results?
The latest statements here come from Structure Therapeutics Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.Where does this GPCR financial data come from?
Quantisnow builds these statements from the structured XBRL data Structure Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.